ERBB2 and breast carcinoma: The discovery that HER2 overexpression was associated with an extremely poor outcome in breast cancer led to the development of the monoclonal antibody trastuzumab and many other agents later, which revolutionized the outcome of patients with HER2-positive breast cancer.